TTFields for Mesothelioma: NovoTTF-100L Tumor Treating Fields Explained

Tumor Treating Fields (TTFields) therapy delivered via the Optune Lua device achieved a median overall survival of 18.2 months in the STELLAR trial when combined with standard chemotherapy—a 50% improvement over the 12.1-month historical benchmark for chemotherapy alone in unresectable malignant pleural mesothelioma.^[1][5]

Key Facts About TTFields for Mesothelioma

• TTFields deliver 150 kHz alternating electric fields through transducer arrays worn on the torso for 18+ hours/day^[1]
• FDA approved the Optune Lua device on May 23, 2019 under the Humanitarian Device Exemption (HDE)^[2]
• STELLAR trial: 18.2-month median OS vs. 12.1-month historical control^[1]
• Epithelioid subtype: 21.2-month median survival; non-epithelioid: 12.1 months^[1]
• 40% objective response rate and 97% disease control rate in STELLAR^[1]
• Median progression-free survival: 7.6 months (vs. 5.7 months for chemo alone)^[1]
• No phase 3 randomized trial in mesothelioma exists—STELLAR was phase 2, single-arm^[6]
• Mesothelioma remains the sole HDE indication in Novocure's portfolio—all other approvals are full PMA^[6]
• Most common side effect: skin irritation at array sites (43% of patients)^[1]
• The TIGER Meso registry (NCT05538806) is currently enrolling ~198 patients for real-world data^[7]

What Are Tumor Treating Fields and How Do They Work Against Mesothelioma?

Tumor Treating Fields are low-intensity (1–3 V/cm), intermediate-frequency (150 kHz for mesothelioma) alternating electric fields delivered continuously through adhesive transducer arrays placed on the patient's torso. The fields disrupt cancer cell division through two primary mechanisms.^[1]

First, TTFields interfere with tubulin alignment during mitotic spindle formation. Dividing cancer cells rely on properly aligned microtubules to separate chromosomes. The alternating electric fields exert forces on these charged and polarizable molecules, disrupting spindle assembly and leading to abnormal chromosome segregation.

Second, TTFields cause dielectrophoretic movement of intracellular organelles toward the dividing cell's cleavage furrow, leading to membrane blebbing and cell death. Because non-dividing cells are minimally affected by these forces, TTFields selectively target rapidly dividing cancer cells while largely sparing normal tissue.

> "TTFields represent a fundamentally different approach to mesothelioma treatment. Unlike chemotherapy, which is a systemic toxin, or immunotherapy, which activates the immune system, TTFields are a physical force that specifically disrupts cell division. The side effect profile reflects this precision—skin irritation at the array sites rather than systemic toxicity." > — David Foster, Executive Director of Client Services, Danziger & De Llano

What Did the STELLAR Trial Show About TTFields Efficacy?

The STELLAR trial (EF-23; NCT02397928) was a prospective, international, phase 2, single-arm study conducted at 12 European sites. It enrolled 80 patients with unresectable, previously untreated malignant pleural mesothelioma between February 2015 and March 2017.^[1]

Patients received continuous TTFields at 150 kHz for a minimum of 18 hours daily, plus up to 6 cycles of pemetrexed (500 mg/m²) with cisplatin (75 mg/m²) or carboplatin every 3 weeks. After completing chemotherapy, patients continued TTFields as maintenance monotherapy until disease progression.

Endpoint	Overall Population	Epithelioid	Non-Epithelioid
Median Overall Survival	18.2 months	21.2 months	12.1 months
1-Year Survival	62.2%	—	—
2-Year Survival	41.9%	—	—
Median PFS	7.6 months	8.3 months	6.5 months
Objective Response Rate	40%	—	—
Disease Control Rate	97%	—	—

The primary endpoint was overall survival compared against the 12.1-month historical control from the Vogelzang 2003 registration trial of pemetrexed plus cisplatin.^[5] The median duration of response was 5.7 months, and median TTFields compliance during the first 3 months was 16.3 hours per day.

> "The STELLAR trial numbers are compelling: 18.2 months median survival, nearly double the historical standard. But I always counsel patients to understand the context. This was a single-arm study of 80 patients, not a randomized trial. The confidence interval ranges from 12.1 to 25.8 months, which means the true benefit could be modest or substantial." > — David Foster, Executive Director of Client Services, Danziger & De Llano

How Does TTFields Compare to Other First-Line Mesothelioma Treatments?

Placing STELLAR in context with other first-line mesothelioma trials reveals competitive but not clearly superior survival outcomes:^[6]

Trial	Treatment	Median OS	ORR	Design
STELLAR (2019)	TTFields + pem/platinum	18.2 months	40%	Phase 2, single-arm
Vogelzang (2003)	Pem + cisplatin	12.1 months	41%	Phase 3, RCT
MAPS (2016)	Pem + cis + bevacizumab	18.8 months	—	Phase 3, RCT
CheckMate 743 (2021)	Nivo + ipi	18.1 months	40%	Phase 3, RCT

The 95% confidence interval for STELLAR's median OS (12.1–25.8 months) overlaps broadly with outcomes from other regimens. Independent reviewers have emphasized that single-arm designs consistently overestimate efficacy compared to randomized comparators. The MAPS and CheckMate 743 trials both used randomized designs and showed similar survival numbers.^[4]

NCCN guidelines (v2.2025) and the ASCO 2025 update list nivolumab plus ipilimumab as the preferred first-line option for non-epithelioid mesothelioma. TTFields is not prominently featured in either guideline, reflecting the absence of phase 3 randomized data.^[3]

What Is the Difference Between HDE Approval and Full FDA Approval?

The distinction between the Humanitarian Device Exemption (HDE) and full Premarket Approval (PMA) is clinically and financially significant for mesothelioma patients considering TTFields.^[2]

The HDE pathway is designed for devices treating rare conditions affecting fewer than 8,000 U.S. patients annually. It requires demonstration of probable benefit rather than the demonstrated effectiveness standard of PMA. The FDA's own approval statement for TTFields in mesothelioma acknowledged that "in the absence of a control group, statistical significance was not determined."^[2]

This lower evidentiary bar has practical consequences. Some private insurers classify TTFields for mesothelioma as investigational based on the HDE pathway. Medicare coverage varies by region. Mesothelioma is now the sole HDE indication in Novocure's portfolio—the company's other four approvals (glioblastoma, NSCLC, pancreatic cancer) all received full PMA based on phase 3 randomized trials.^[6]

> "Understanding the regulatory pathway matters for patients. The HDE approval means TTFields has shown probable benefit for mesothelioma, but the evidence bar is lower than what the FDA requires for other cancers. This affects insurance coverage and should be part of the treatment discussion with your oncologist." > — David Foster, Executive Director of Client Services, Danziger & De Llano

What Are the Side Effects of TTFields Therapy?

TTFields therapy has a distinct side effect profile that differs substantially from chemotherapy and immunotherapy. The most common adverse event is skin irritation at the transducer array sites, reported in approximately 43% of STELLAR trial patients.^[1]

Skin reactions range from mild erythema (redness) to more significant contact dermatitis that may require array repositioning or temporary treatment breaks. Proper skin care, regular array rotation, and topical corticosteroids manage most skin reactions effectively.

TTFields do not cause the systemic side effects common with chemotherapy, such as severe nausea, hair loss, immunosuppression, or peripheral neuropathy. The device requires shaving the treatment area and changing arrays every 3 to 4 days. The practical burden of wearing the device for 18+ hours daily is significant—real-world U.S. compliance data show median wear time of 12.5 hours per day, substantially below the 16.3 hours achieved in the STELLAR trial.

What Are the Ongoing Studies for TTFields in Mesothelioma?

The principal ongoing TTFields study in mesothelioma is the TIGER Meso registry (NCT05538806), a post-authorization, prospective, observational study.^[7]

• Sponsor: NovoCure Ltd.
• Principal Investigator: Giovanni Luca Ceresoli (Humanitas Gavazzeni Hospital, Bergamo, Italy)
• Enrollment target: ~198 patients at 23 centers
• Start date: September 6, 2022
• Purpose: Collect real-world data on TTFields use in routine clinical practice, including combinations with immunotherapy and various chemotherapy regimens

TIGER Meso is observational, not interventional—it tracks outcomes in patients already receiving TTFields rather than randomizing treatment. No phase 3 randomized controlled trial of TTFields in mesothelioma is registered on ClinicalTrials.gov as of March 2026.^[7]

Novocure received FDA PMA for TTFields in metastatic NSCLC (2024, based on the phase 3 LUNAR trial) and locally advanced pancreatic cancer (February 2026, based on the phase 3 PANOVA-3 trial). The progression to phase 3 trials and PMA in other cancers underscores that the mesothelioma evidence base remains at the phase 2 level.

How Can Patients Access TTFields Treatment?

Patients interested in TTFields for mesothelioma should discuss it with their oncology team at a mesothelioma treatment center. Key access considerations include:

Eligibility: TTFields is approved for adult patients with unresectable, locally advanced or metastatic malignant pleural mesothelioma, used concurrently with pemetrexed and platinum-based chemotherapy. Patients must have adequate performance status and no implanted electronic medical devices in the torso.

Insurance: Coverage varies by insurer and region. Novocure offers patient support programs including insurance navigation assistance. Some patients may need to appeal initial coverage denials, particularly with private insurers that classify the device as investigational.

Treatment centers: TTFields is available at major cancer centers across the United States. The TIGER Meso registry sites may offer access within a structured data collection framework.

Financial support: Mesothelioma patients may be eligible for asbestos trust fund compensation and lawsuit recoveries that can offset treatment costs, including device expenses not covered by insurance. Take our free case assessment to evaluate your compensation options.

> "Cost should never be the reason a mesothelioma patient doesn't pursue a promising treatment. Between trust fund claims, lawsuit compensation, and insurance advocacy, most patients can access the treatments they need. The legal and medical paths should work together from day one." > — David Foster, Executive Director of Client Services, Danziger & De Llano

What Questions Should Patients Ask Their Oncologist About TTFields?

Patients considering TTFields should have an informed discussion with their mesothelioma specialist. Key questions include:

1. Am I a candidate for TTFields based on my mesothelioma subtype and stage? Epithelioid patients showed the strongest survival benefit (21.2 months) in STELLAR.
2. How does TTFields compare to immunotherapy for my specific case? CheckMate 743 showed particular benefit for non-epithelioid histology with nivolumab plus ipilimumab.^[4]
3. Will my insurance cover TTFields? The HDE pathway means coverage is not guaranteed. Ask about appeal processes and Novocure's patient support programs.
4. What is the realistic wear time I should expect? Trial compliance was 16.3 hours/day, but real-world data shows 12.5 hours. Higher compliance may correlate with better outcomes.
5. Can TTFields be combined with immunotherapy? Early data from other cancers suggest potential synergy, and TIGER Meso is tracking immunotherapy combinations in mesothelioma.

For a comprehensive evaluation of your treatment options and compensation rights, contact a mesothelioma specialist attorney who can coordinate legal and medical pathways simultaneously.^[8]

References

1. Ceresoli, G.L., et al. "Final Results of Phase II STELLAR Trial: TTFields With Chemotherapy in Unresectable Malignant Pleural Mesothelioma." The Lancet Oncology, 2019. PubMed
2. U.S. FDA. "FDA Approval of NovoTTF-100L System - HDE H180002." FDA
3. NCCN. "Malignant Pleural Mesothelioma: Clinical Practice Guidelines v2.2025." NCCN
4. Baas, P., et al. "First-Line Nivolumab Plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma (CheckMate 743)." The Lancet, 2021. PubMed
5. Vogelzang, N.J., et al. "Pemetrexed Plus Cisplatin Versus Cisplatin Alone." Journal of Clinical Oncology, 2003. PubMed
6. Ceresoli, G.L. & Gianoncelli, L. "Tumor Treating Fields in Malignant Pleural Mesothelioma: A Comprehensive Review." Current Treatment Options in Oncology, 2025. PubMed
7. ClinicalTrials.gov. "TIGER Meso Study - NCT05538806." ClinicalTrials.gov
8. NCI. "Malignant Mesothelioma Treatment - Patient Version." NCI
9. NCI SEER. "Mesothelioma: SEER Stat Fact Sheets." SEER
10. WikiMesothelioma. "Mesothelioma Quick Facts." WikiMesothelioma
11. WikiMesothelioma. "Clinical Trials for Mesothelioma." WikiMesothelioma
12. WikiMesothelioma. "Treatment Options Overview." WikiMesothelioma